Andrew Katz, DPM
Podiatrist · Palmdale, CANPI 1780661900
Payments from drug & device makers
What this record shows
15 manufacturers reported payments, led by Treace Medical Concepts, Inc. at 42.2% of the total. Reporting peaked in 2024 at $1,737 and has fallen 97.0% since, to $52 in 2025.
Across 60 payments — averaging $61.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Treace Medical Concepts, Inc.$2K
- Biotissue Holdings Inc.$1K
- Smith+Nephew$343
- Integra Lifesciences Corporation$150
- Cardiovascular Systems Inc.$117
- Organogenesis Inc.$57
- plus $241 from 9 others
What the payments were for
- Travel & lodging$2,11357%
- Food & beverage$1,56643%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Treace Medical Concepts, Inc. | 6 | $1,554 |
| Biotissue Holdings Inc. | 18 | $1,218 |
| Smith+Nephew | 17 | $343 |
| Integra Lifesciences Corporation | 1 | $150 |
| Cardiovascular Systems Inc. | 1 | $117 |
| Organogenesis Inc. | 3 | $57 |
| Nevro Corp. | 2 | $53 |
| Johnson & Johnson | 3 | $47 |
| Acell, Inc. | 2 | $29 |
| Paragon 28, Inc. | 2 | $29 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Stryker | 1 | $20 |
| Orthofix Medical, Inc. | 1 | $17 |
| Zyla Life Sciences, Inc. | 1 | $13 |
| Next Science LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lapiplasty System$1,484
- NEOX$875
- CLARIX$875
- INTEGRA$450
- INTEGRA DERMAL REGENERATION TEMPLATE$150
- PRIMATRIX$150
- Peripheral Orbital Atherectomy System$117
How this compares
$3,679 in reported general payments places this provider in the 80th percentile of 721 podiatrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ammonium Lactate | 73 | $1,347 |
| Ketoconazole | 42 | $767 |
| Lidocaine | 15 | $745 |
| Ciclopirox | 33 | $674 |
| Gabapentin | 44 | $480 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 33 | $436 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 12 | $299 |
| Cephalexin | 55 | $194 |
| Ibuprofen | 21 | $185 |
| SsdSilver Sulfadiazine | 19 | $173 |
| Terbinafine Hcl | 21 | $118 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $75 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Palmdale
- Shannon RushPleasanton$1.9M
- Babak BaravarianSanta Monica$1.1M
- Robert KleimanCalexico$913K
- Bruce LawrenceOceanside$810K
- David ArmstrongLos Angeles$695K
- Philip WrotslavskyPoway$269K
- Travis WestermeyerEncinitas$158K
- Adrienne EstesPomona$129K
- Ronald LiebermanEncinitas$109K
- Matthew DoyleMountain View$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.